The enrichment of HBV immune-escape mutations during nucleoside/nucleotide analogue therapy.

Abstract:

BACKGROUND:Drug-resistant HBV mutants frequently arise during nucleoside/nucleotide analogue (NA) therapy, while the resistance mutations on polymerase also have consequent changes in the S protein. The enrichment of immune-escape mutations was negatively correlated with hepatitis B surface antigen (HBsAg) clearance under NA therapy. This study aims to characterize the variability of HBV polymerase and surface antigen in patients with virological breakthrough under NA therapy. METHODS:From 2012 to 2014, serum samples were collected from 156 patients with chronic hepatitis B infection, who had experienced NA therapy for at least 24 weeks and displayed virological breakthrough, while 165 HBV carriers without NA treatment were also enrolled. HBV DNA was quantified and polymerase reverse transcriptase domain was amplified and sequenced. RESULTS:A total of 97 patients in the NA treatment group had resistance mutations, with rtM204I/V/S being the most common substitution (78 of 97), while no resistance mutations were detected in the treatment-naive group. Various escape mutations were detected, and the detection rate was significantly higher in the NA treatment group (38, 24.4%) than that of treatment-naive group (18, 10.9%; P<0.05). Except for the combination of sP120T+sA128V, other double combinations (n=11) were only detected in the NA treatment group, and nine of these combinations in the treatment group were detected in HBV variants without antiviral resistance mutations. CONCLUSIONS:Antiviral resistance mutations were selected by a long duration of NA therapy. Virological breakthrough was not only attributed to the emergence of resistance mutations, but may also be associated with the enrichment of immune-escape mutations.

journal_name

Antivir Ther

journal_title

Antiviral therapy

authors

Shan M,Shen Z,Sun H,Zheng J,Zhang M

doi

10.3851/IMP3156

subject

Has Abstract

pub_date

2017-01-01 00:00:00

pages

717-720

issue

8

eissn

1359-6535

issn

2040-2058

journal_volume

22

pub_type

杂志文章
  • Prevalence of rilpivirine resistance in people starting antiretroviral treatment in Argentina.

    abstract:BACKGROUND:Rilpivirine-based regimens are now preferred or alternative first-line regimens according to many HIV treatment guidelines. Recently, a surveillance study conducted in Argentina determined that prevalence of pretreatment resistance to first-generation non-nucleoside reverse transcriptase inhibitors (NNRTIs) ...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP3147

    authors: Bissio E,Barbás MG,Kademián S,Bouzas MB,Salomón H,Cudolá A,Giuliano SF,Falistocco C

    更新日期:2017-01-01 00:00:00

  • Preventing and treating secondary bacterial infections with antiviral agents.

    abstract::Bacterial super-infections contribute to the significant morbidity and mortality associated with influenza and other respiratory virus infections. There are robust animal model data, but only limited clinical information on the effectiveness of licensed antiviral agents for the treatment of bacterial complications of ...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,评审

    doi:10.3851/IMP1730

    authors: McCullers JA

    更新日期:2011-01-01 00:00:00

  • Mutual pharmacokinetic interactions between bosentan and lopinavir/ritonavir in healthy participants.

    abstract:BACKGROUND:We aimed to investigate the extent of pharmacokinetic drug interactions between bosentan and a fixed combination of lopinavir/ritonavir. METHODS:This was a three-way crossover study in 12 healthy male participants treated with bosentan (125 mg twice daily) and lopinavir/ritonavir (400/100 mg twice daily) al...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,随机对照试验

    doi:10.3851/IMP1506

    authors: Dingemanse J,van Giersbergen PL,Patat A,Nilsson PN

    更新日期:2010-01-01 00:00:00

  • Predicting antiretroviral drug resistance from the latest or the cumulative genotype.

    abstract:BACKGROUND:This study evaluates the added benefit when estimating antiretroviral drug resistance of combining all available resistance test results in a cumulative genotype relative to using the latest genotype alone. METHODS:The prevalence of resistance and genotypic sensitivity scores (GSS) predicted by the latest a...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP1753

    authors: Garcia F,Alvarez M,Fox Z,Garcia-Diaz A,Guillot V,Johnson M,Chueca N,Phillips A,Hernández-Quero J,Geretti AM

    更新日期:2011-01-01 00:00:00

  • Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods.

    abstract::Infection with influenza viruses, including seasonal, avian and pandemic viruses, remains a worldwide public health problem. Although influenza virus infection is both vaccine preventable and drug treatable, high rates of mutation and reassortment of viruses can result in reduced effectiveness of vaccines or drugs. Cu...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,评审

    doi:10.3851/IMP2067

    authors: Nguyen HT,Fry AM,Gubareva LV

    更新日期:2012-01-01 00:00:00

  • Primary, post-primary and non-specific immunoglobulin M responses in HCV infection.

    abstract::Delayed and variable antibody responses to HCV make it difficult to diagnose acute HCV infection reliably. Immunoglobulin (Ig)M and IgG anti-HCV may be observed simultaneously as disease persists. IgM plays a key role in mixed cryoglobulinemia (MC), an immune complex disease strongly associated with persistent HCV inf...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,评审

    doi:10.3851/IMP2222

    authors: Dustin LB,Charles ED

    更新日期:2012-01-01 00:00:00

  • Persistent brain abnormalities in antiretroviral-naive HIV patients 3 months after HAART.

    abstract:BACKGROUND:Proton magnetic resonance spectroscopy (1H-MRS) and neuropsychological tests may be useful for monitoring the effectiveness of highly active antiretroviral therapy (HAART) in HIV-associated brain injury. We aimed to evaluate whether brain abnormalities will improve 3 months after HAART. METHOD:Thirty-three ...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Chang L,Ernst T,Witt MD,Ames N,Walot I,Jovicich J,DeSilva M,Trivedi N,Speck O,Miller EN

    更新日期:2003-02-01 00:00:00

  • Genital secretion HIV RNA shedding in HIV-positive patients on ritonavir-boosted protease inhibitor monotherapy or standard combination ART: a cross-sectional sub-study from the PIVOT Trial.

    abstract:BACKGROUND:Protease inhibitors (PI) have relatively low penetration into the genital tract, raising concerns about the potential for genital HIV RNA shedding in patients taking PI-based regimens, particularly PI monotherapy (PI-mono). METHODS:We measured HIV RNA and PI drug concentrations in samples of semen, cervico-...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP3340

    authors: Arenas-Pinto A,Stöhr W,Khoo S,Clarke A,Beeching N,Warwick Z,Lee V,Else L,Wiggins R,Ferns B,Nastouli E,Dunn D,Lacey CJ,Paton NI,Protease Inhibitor monotherapy Versus Ongoing Triple therapy (PIVOT) Genital Secretion sub-study T

    更新日期:2020-01-01 00:00:00

  • Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients.

    abstract:BACKGROUND:Mutations in the genome of HIV conferring drug resistance are a major reason for the failure of antiretroviral therapy, but they often compromise viral fitness. Protease (PR) cleavage site (CS) mutations could compensate for impaired replication capacity of drug-resistant viruses. PATIENTS AND METHODS:We an...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Verheyen J,Litau E,Sing T,Däumer M,Balduin M,Oette M,Fätkenheuer G,Rockstroh JK,Schuldenzucker U,Hoffmann D,Pfister H,Kaiser R

    更新日期:2006-01-01 00:00:00

  • Stability of liver fibrosis among HCV-infected injection drug users.

    abstract:BACKGROUND:There are few published data characterizing patterns of liver stiffness measurements (LSMs) among HCV-infected persons and their potential impact on clinical decisions (for example, deferring treatment and hepatocellular carcinoma surveillance). METHODS:A total of 591 HCV-infected injection drug users in a ...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP2085

    authors: Mehta SH,Kirk GD,Astemborski J,Sulkowski MS,Afdhal NH,Thomas DL

    更新日期:2012-01-01 00:00:00

  • Long-term lamivudine treatment is associated with a good maintained response in severe acute exacerbation of chronic HBeAg-negative hepatitis B.

    abstract::Hepatitis B e antigen (HBeAg)-negative chronic hepatitis B is difficult to treat and there is little long-term data for lamivudine treatment of severe acute exacerbation. We report a prospective, consecutive cohort of severe acute exacerbation of HBeAg-negative chronic hepatitis B patients treated by lamivudine betwee...

    journal_title:Antiviral therapy

    pub_type: 临床试验,杂志文章

    doi:

    authors: Chan HL,Wong VW,Hui AY,Tsang SW,Chan JL,Chan HY,Wong GL,Sung JJ

    更新日期:2006-01-01 00:00:00

  • Targeting human papillomavirus genome replication for antiviral drug discovery.

    abstract::Human papillomavirus (HPV) infections are a major human health problem; they are the cause of recurrent benign warts and of several cancers of the anogenital tract and head and neck region. Although there are two prophylactic HPV vaccines that could, if used universally, prevent as many as two-thirds of HPV-induced ca...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,评审

    doi:10.3851/IMP2612

    authors: Archambault J,Melendy T

    更新日期:2013-01-01 00:00:00

  • Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures.

    abstract:OBJECTIVES:To assess potential pharmacokinetic (PK) interactions between atazanavir (ATV, 300 mg, once daily) and lopinavir (LPV, 400 mg, twice daily), both boosted by ritonavir (RTV, 100 mg). DESIGN:Two-parallel groups, addition of LPV in patients receiving ATV (n=6), and addition of ATV in patients receiving LPV (n=...

    journal_title:Antiviral therapy

    pub_type: 临床试验,杂志文章

    doi:

    authors: Colombo S,Buclin T,Franc C,Guignard N,Khonkarly M,Tarr PE,Rochat B,Biollaz J,Telenti A,Decosterd LA,Cavassini M

    更新日期:2006-01-01 00:00:00

  • Reduced airborne transmission of oseltamivir-resistant pandemic A/H1N1 virus in ferrets.

    abstract:BACKGROUND:The H275Y neuraminidase mutation conferring oseltamivir resistance has been reported in several pandemic A/H1N1 (pH1N1) isolates. We sought to evaluate transmission of this mutant virus through the direct contact and the airborne (aerosol and droplet) routes in the ferret model. METHODS:Groups of four ferre...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP1794

    authors: Hamelin ME,Baz M,Bouhy X,Beaulieu E,Dubé K,Mallett C,Boivin G

    更新日期:2011-01-01 00:00:00

  • Identification of nonsense mutations in hepatitis B virus S gene in patients with hepatocellular carcinoma developed after lamivudine therapy.

    abstract:BACKGROUND:Lamivudine is widely used in patients with chronic hepatitis B virus (HBV) infection. In cirrhotic patients, long-term lamivudine therapy significantly reduced the risk of hepatocellular carcinoma (HCC). However, in a small but substantial portion of patients, HCC still developed despite lamivudine therapy. ...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Lai MW,Huang SF,Hsu CW,Chang MH,Liaw YF,Yeh CT

    更新日期:2009-01-01 00:00:00

  • Impact of CCR5, integrase and protease inhibitors on human endothelial cell function, stress, inflammation and senescence.

    abstract:BACKGROUND:Ageing HIV-infected patients present an increased incidence of cardiovascular diseases, endothelial dysfunction being an early alteration. Some protease inhibitors (PIs) have been shown to increase the risk of cardiovascular disease. We evaluated here the effects of CCR5 or integrase inhibitors as compared t...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP3160

    authors: Afonso P,Auclair M,Caron-Debarle M,Capeau J

    更新日期:2017-01-01 00:00:00

  • Pleconaril-resistant chronic parechovirus-associated enteropathy in agammaglobulinaemia.

    abstract::A 14 year old common variable immunodeficiency patient developed severe protein-losing enteropathy. A chronic enteral infection with human parechovirus type 1 and norovirus was diagnosed. Treatment strategies aimed at virus eradication and providing supportive care were ineffective. The antipicornavirus agent pleconar...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP1792

    authors: van de Ven AA,Douma JW,Rademaker C,van Loon AM,Wensing AM,Boelens JJ,Sanders EA,van Montfrans JM

    更新日期:2011-01-01 00:00:00

  • Expert opinion on managing chronic HCV in patients with neuropsychiatric manifestations.

    abstract::Neurological manifestations of HCV infection appear to be under-recognized in clinical practice despite the majority of HCV-infected patients experiencing symptoms such as fatigue, depression and cognitive dysfunction. There is also growing evidence for a link between HCV infection and an increased risk of Parkinson's...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,评审

    doi:10.3851/IMP3245

    authors: Forton D,Weissenborn K,Bondin M,Cacoub P

    更新日期:2018-01-01 00:00:00

  • Incidence of liver cirrhosis in HIV-infected patients with chronic hepatitis B or C in the era of highly active antiretroviral therapy.

    abstract:BACKGROUND:Longitudinal assessment of liver fibrosis with transient elastometry (TE) in patients with chronic viral hepatitis is becoming routine clinical practice in many clinics, as this procedure is non-invasive, easy to perform and relatively inexpensive, allowing early detection of cirrhosis. Herein, we examine th...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP1630

    authors: Tuma P,Medrano J,Resino S,Vispo E,Madejón A,Sánchez-Piedra C,Rivas P,Labarga P,Martín-Carbonero L,Barreiro P,Soriano V

    更新日期:2010-01-01 00:00:00

  • Use of newer antiretroviral agents, darunavir and etravirine with or without raltegravir, in pregnancy: a report of two cases.

    abstract:BACKGROUND:Although antiretroviral therapy during pregnancy is associated with significant reductions in the risk of vertical transmission of HIV, attainment of this outcome in highly treatment-experienced pregnant women might be complicated by the lack of active drugs available to assemble a potent regimen. The recent...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP1558

    authors: Jaworsky D,Thompson C,Yudin MH,Bitnun A,Brophy J,Samson L,Antoniou T,Loutfy MR

    更新日期:2010-01-01 00:00:00

  • Protective murine and human monoclonal antibodies against eczema vaccinatum.

    abstract:BACKGROUND:Eczema vaccinatum is the most common severe pathology associated with smallpox vaccination (vaccinia virus), occurring at high rates among individuals with a previous history of atopic dermatitis (atopic eczema). METHODS:Monoclonal antibodies capable of neutralizing vaccinia virus, anti-H3 and anti-B5, were...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP1717

    authors: Tomimori Y,Kawakami Y,McCausland MM,Ando T,Koriazova L,Kato S,Kawakami T,Crotty S

    更新日期:2011-01-01 00:00:00

  • Low density lipoprotein apolipoprotein B metabolism in treatment-naive HIV patients and patients on antiretroviral therapy.

    abstract:BACKGROUND:Dyslipidaemia and lipodystrophy have been described in treated HIV patients and in a small percentage of untreated HIV patients. Lipodystrophy in these patients has been shown to be associated with a lower expression of low density lipoprotein (LDL) receptors. METHODS:We have investigated the effect of anti...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Umpleby AM,Das S,Stolinski M,Shojaee-Moradie F,Jackson NC,Jefferson W,Crabtree N,Nightingale P,Shahmanesh M

    更新日期:2005-01-01 00:00:00

  • Is there a need for liver disease monitoring in HIV patients in Africa?

    abstract::Liver disease is one of the leading causes of death in HIV-infected individuals from Europe and North America and has been attributed mainly to coinfection with hepatotropic viruses. Little data, however, has so far become available on liver disease in HIV-infected individuals from Africa. Results from a first study o...

    journal_title:Antiviral therapy

    pub_type: 评论,杂志文章

    doi:10.3851/IMP1787

    authors: Rockstroh JK,Peters L,Wedemeyer H

    更新日期:2011-01-01 00:00:00

  • The protease inhibitors ritonavir and saquinavir influence lipid metabolism: a pig model for the rapid evaluation of new drugs.

    abstract:BACKGROUND:Studies of the effects of antiretroviral drugs on lipid metabolism are limited by the availability of suitable models. We have thus developed an animal model utilising Göttingen mini-pigs. The normal lipid metabolism of mini-pigs closely reflects that of humans and they are expected to have similar reactions...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP1509

    authors: Petersen E,Mu H,Porsgaard T,Bertelsen LS

    更新日期:2010-01-01 00:00:00

  • Successful treatment of rapidly progressing severe fever with thrombocytopenia syndrome with neurological complications using intravenous immunoglobulin and corticosteroid.

    abstract::Since the first report of severe fever with thrombocytopenia syndrome (SFTS) in China, diagnostic methods have evolved. Despite definitive diagnoses, SFTS management has focused on prevention and supportive care. Although conservative treatment is effective for mild cases, there is an urgent need for an effective ther...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP3036

    authors: Kim UJ,Kim DM,Ahn JH,Kang SJ,Jang HC,Park KH,Jung SI

    更新日期:2016-01-01 00:00:00

  • Tenofovir-based antiretroviral therapy in 
HBV-HIV coinfection: results from the TREAT Asia HIV Observational Database.

    abstract:BACKGROUND:The World Health Organization recommends HBV-HIV-coinfected individuals start antiretroviral therapy containing tenofovir. Here we describe first-line tenofovir use and treatment outcomes in coinfected patients in Asia. METHODS:HBV surface antigen positive patients enrolled in the TREAT Asia HIV Observation...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,多中心研究

    doi:10.3851/IMP2972

    authors: Boettiger DC,Kerr S,Ditangco R,Chaiwarith R,Li PC,Merati TP,Pham TT,Kiertiburanakul S,Kumarasamy N,Vonthanak S,Lee CK,Van Kinh N,Pujari S,Wong WW,Kamarulzaman A,Zhang F,Yunihastuti E,Choi JY,Oka S,Ng OT,Kantipong

    更新日期:2016-01-01 00:00:00

  • External quality assessment of HLA-B*5701 reporting: an international multicentre survey.

    abstract:OBJECTIVES:HLA-B*5701 strongly predicts abacavir hypersensitivity (HSR), but implementation of effective routine screening into clinical practice requires testing be practical and accurate. We tested the proficiency of HLA-B*5701 typing among laboratories using sequence-specific primer PCR. DESIGN AND METHODS:DNA pane...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,多中心研究

    doi:

    authors: Hammond E,Almeida CA,Mamotte C,Nolan D,Phillips E,Schollaardt TA,Gill MJ,Angel JB,Neurath D,Li J,Giulivi T,McIntyre C,Koultchitski G,Wong B,Reis M,Rachlis A,Cole DE,Chew CB,Neifer S,Lalonde R,Roger M,Jeanneau A

    更新日期:2007-01-01 00:00:00

  • Characterization of HCV resistance from a 3-day monotherapy study of voxilaprevir, a novel pangenotypic NS3/4A protease inhibitor.

    abstract:BACKGROUND:Voxilaprevir (VOX; GS-9857) is a pangenotypic HCV NS3/4A protease inhibitor (PI) with potent antiviral activity against HCV genotypes (GTs) 1-6 and improved coverage of GT1 NS3 resistance-associated substitutions (RAS) associated with other HCV PIs. In a 3-day Phase Ib monotherapy study in patients infected ...

    journal_title:Antiviral therapy

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.3851/IMP3202

    authors: Lawitz E,Yang JC,Stamm LM,Taylor JG,Cheng G,Brainard DM,Miller MD,Mo H,Dvory-Sobol H

    更新日期:2018-01-01 00:00:00

  • Darunavir minimum plasma concentration and ritonavir-boosted darunavir monotherapy outcome in HIV-infected patients.

    abstract:BACKGROUND:This study aimed to evaluate whether low darunavir (DRV) minimum plasma concentration (Cmin) values contribute to virological outcomes during DRV/ritonavir monotherapy (mtDRV/rtv). METHODS:This was a prospective observational single-arm 96-week efficacy study in virologically suppressed subjects on triple t...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP2722

    authors: Gutierrez-Valencia A,Torres-Cornejo A,BenMarzouk-Hidalgo OJ,Ruiz-Valderas R,Lluch A,Viciana P,López-Cortés LF

    更新日期:2014-01-01 00:00:00

  • Intravenous ribavirin for hantavirus pulmonary syndrome: safety and tolerance during 1 year of open-label experience. Ribavirin Study Group.

    abstract::Intravenous ribavirin was provided non-selectively for investigational open-label use among persons with suspected hantavirus pulmonary syndrome (HPS) in the United States between 4 June 1993 and 1 September 1994. Therapy was initiated prior to laboratory confirmation of hantavirus infection because most deaths from H...

    journal_title:Antiviral therapy

    pub_type: 临床试验,杂志文章

    doi:

    authors: Chapman LE,Mertz GJ,Peters CJ,Jolson HM,Khan AS,Ksiazek TG,Koster FT,Baum KF,Rollin PE,Pavia AT,Holman RC,Christenson JC,Rubin PJ,Behrman RE,Bell LJ,Simpson GL,Sadek RF

    更新日期:1999-01-01 00:00:00